A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® (ARD-3150, Dual Release Ciprofloxacin for Inhalation) in subjects who have a lung infection that includes the bacteria Pseudomonas aeruginosa due to non-cystic fibrosis bronchiectasis

• Register: EUCTR
• Last refreshed on: 17 January 2022
• Main ID: EUCTR2013-005348-28-RO
• Date of registration: 30/05/2014
• Prospective Registration: Yes
• Primary sponsor: Aradigm Corporation
• Public title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® (ARD-3150, Dual Release Ciprofloxacin for Inhalation) in subjects who have a lung infection that includes the bacteria Pseudomonas aeruginosa due to non-cystic fibrosis bronchiectasis
• Scientific title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3) - Pulmaquin® with Non-Cystic Fibrosis Bronchiectasis (ORBIT 3)
• Date of first enrolment: 30/07/2014
• Target sample size: 255
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-005348-28
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes; Randomised: yes; Open: no; Single blind: no; Double blind: yes; Parallel group: yes; Cross over: no; Other: no; If controlled, specify comparator, Other Medicinial Product: no; Placebo: yes; Other: no; Number of treatment arms in the trial: 2
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Australia, Canada, Georgia, Germany, Hungary, Ireland, Israel, Italy, Latvia, Netherlands, New Zealand, Poland, Romania, South Africa, Spain, United Kingdom, United States

Contacts

• Name: Chief Medical Officer
• Affiliation: Aradigm Corporation

• Name: Chief Medical Officer
• Affiliation: Aradigm Corporation

Key inclusion & exclusion criteria

Inclusion criteria:
Subjects will be entered into this study only if they meet all of the following criteria:
1. Are willing and able to provide written informed consent.
2. Are males or females who are 18 year of age or older and are able to
walk.
3. Have had a confirmed diagnosis of non-CF bronchiectasis per
computerized tomography showing bronchial wall dilatation (internal
bronchial lumen diameter greater than accompanying pulmonary artery
or lack of tapering) with or without bronchial wall thickening.
4. Have a documented history of at least 2 pulmonary exacerbations
treated with courses of antibiotics within the last 12 months.
5. Have been off any antibiotic treatment for a minimum of 28 days prior
to Visit 1, except for macrolides (azithromycin or erythromycin) used
chronically at a stable dose.
6. Have forced expiratory volume in 1 second (FEV1) = 25% of predicted
values at the Screening Visit (Visit 0).
7. Have positive documented P. aeruginosa in a sputum/deep-throat
swab culture (or bronchoalveolar lavage [BAL] or bronchoscopic
specimen) prior to the Screening Visit (Visit 0).
8. Have positive P. aeruginosa in the sputum/deep-throat swab culture
collected at the Screening Visit (Visit 0). If sputum sample is negative,
sputum/swab culture can be repeated on up to 3 occasions during
Screening to document P. aeruginosa presence.
9. Are clinically stable and capable of performing the 6mwt without
supplemental oxygen.
10. Are willing and able to comply with the requirements for
participation in the study.
11. Female subjects of childbearing potential must have a negative
pregnancy test at the Screening Visit and must use an acceptable
method of contraception for at least 3 months prior to the first dose of
study drug and for 28 days after the last dose of study drug. Acceptable
methods of contraception for women are orally administered or
implantable hormonal contraceptives, surgical intervention, intrauterine
device (IUD), and sexual abstinence. To be considered "not of
childbearing potential", female subjects must be postmenopausal for at
least 1 year as confirmed by an elevated follicle-stimulating hormone
(FSH) level (= 30 mIU/mL) at Screening and 1 year of amenorrhea, or
have been irreversibly surgically sterilized by hysterectomy,
oophorectomy, or bilateral tubal ligation for at least 3 months prior to
the first dose of study drug. Male subjects whose female partners are of
childbearing potential (definition as above) must agree to use an
acceptable method of birth control for the duration of study treatment
and for 28 days after the last dose of study drug.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 55

Exclusion criteria:
Subjects will be randomized into this study only if they meet none of the following criteria:
1. Have a pulmonary exacerbation during the Screening Phase (between
Visit 0 and randomization), defined as requiring acute treatment with
inhaled, oral, or intravenous antibiotics prior to the first dose of study
drug.
2. Have a clinical diagnosis of CF.
3. Have primary diagnosis of Chronic Obstructive Pulmonary Disease
(COPD) related to smoking history of greater than 10 pack years.
4. Have a current diagnosis of active allergic bronchopulmonary
aspergillosis.
5. Have received any intravenous, oral, or inhaled anti-pseudomonal
antibiotic (except chronic macrolides erythromycin or azithromycin with
a stable dose) within 28 days prior to Visit 1.
6. Have an allergy to ciprofloxacin, gemifloxacin, levofloxacin,
moxifloxacin, or norfloxacin.
7. Have a known allergy to soy products.
8. Have used tizanidine within 28 days prior to Visit 1 and would need to
use tizanidine during the study (because tizanidine is contraindicated
due to a PK interaction with ciprofloxacin).
9. Have initiated supplemental oxygen within 28 days prior to Visit 1.
10. Have used any intravenous or intramuscular corticosteroid or have
used oral corticosteroid > 10 mg/day or > 20 mg every other day within
28 days of Visit 1.
11. Have had changes in either the treatment regimen or initiation of
treatment with any of the following medications within 28 days prior to
Visit 1:
a. Macrolides, e.g., azithromycin or erythromycin
b. Inhaled hypertonic saline or inhaled mannitol
c. Mucolytics
d. Bronchodilator medications
e. Oral corticosteroid
12. Have had changes in physiotherapy technique or frequency within 28
days prior to Visit 1.
13. Have a history of solid organ (e.g., lung) transplantation.
14. Have a non-tuberculosis mycobacterial infection requiring treatment.
15. Have active tuberculosis.
16. Have serum creatinine levels = 2.0x upper limit of normal (ULN) at
the Screening Visit (Visit 0).
17. Have serum transaminase levels > 3x ULN at the Screening Visit
(Visit 0).
18. Have a febrile illness within 1 week prior to Visit 1.
19. Have had massive hemoptysis (greater than or equal to 300 mL or
requiring blood transfusion) within 6 months prior to Visit 1.
20. Have received an investigational drug or device within 28 days prior
to Visit 1.
21. Have any serious or active medical or psychiatric illness, which in the
opinion of the Investigator, would interfere with subjects' treatment,
assessment, or compliance with the protocol.
22. Have a history or suspicion of unreliability, poor cooperation, or noncompliance
with medical treatment.
23. Are unable to use nebulizers.
24. Are unable either to understand the instruction for use of the study
drug or to complete the Quality of Life Questionnaire-Bronchiectasis
(QoL-B) at Visit 1.
25. Have previously been enrolled in this study.
26. Are pregnant, plan to become pregnant during this study, are nursing
mothers or are unwilling to use an acceptable method of contraception
for the duration of the study.
27. Have any other condition that, in the opinion of the Investigator,
would prohibit the subject from participating in the study.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis.
MedDRA version: 17.0 Level: PT Classification code 10057582 Term: Lung infection pseudomonal System Organ Class: 10021881 - Infections and infestations
MedDRA version: 17.0 Level: LLT Classification code 10006446 Term: Bronchiectasis NOS System Organ Class: 100000004855

Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Intervention(s)

Product Name: Pulmaquin®
Product Code: ARD-3150
Pharmaceutical Form: Nebuliser solution
INN or Proposed INN: Ciprofloxacin Hydrochloride
CAS Number: 86483-48-9
Current Sponsor code: Ciprofloxacin for Inhalation (CFI)
Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Ciprofloxacin Hydrochloride
CAS Number: 86483-48-9
Current Sponsor code: Free Ciprofloxacin for Inhalation (FCI)
Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Nebuliser solution
Route of administration of the placebo: Inhalation use

Primary Outcome(s)

Main Objective: The main objective of this study is to evaluate the efficacy of Pulmaquin compared to placebo in the management of chronic lung infections with P. aeruginosa (a type of bacteria) in subjects with non-cystic fibrosis bronchiectasis by evaluating the time to first pulmonary exacerbation (worsening).

Primary end point(s): The primary efficacy endpoint of this study is the time to first pulmonary
exacerbation from baseline (Day 1) to Week 48.

Secondary Objective: The secondary objectives of this study are to evaluate:
? Efficacy of Pulmaquin compared to placebo as assessed by clinical outcomes (including pulmonary exacerbations), pulmonary function, patient-reported outomes, and exercise testing in the Double-Blind Phase.
? Microbiological response.
? Safety and tolerability of Pulmaquin compared to placebo in the Double-Blind Phase.
? Safety and tolerability of Pulmaquin in the Open-Label Extension.

Timepoint(s) of evaluation of this end point: From baseline (Day 1) to Week 48.

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: From baseline (Day 1) to Week 48.

Secondary end point(s): - Number of pulmonary exacerbations from baseline (Day 1) to Week 48.
- Number of severe pulmonary exacerbations from baseline (Day 1) to
Week 48.
- Change in Respiratory Symptoms Domain score of Qol-B from baseline
(Day 1) to Week 48.

Secondary ID(s)

NCT01515007

2013-005348-28-GB

ARD-3150-1201

Source(s) of Monetary Support

Aradigm Corporation

Ethics review

Status: Approved
Approval date: 30/07/2014
Contact:

Results

• Results available: Yes
• Date Posted: 25/04/2018
• Date Completed: 14/10/2016
• URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-005348-28/results